CANbridge Pharmaceuticals, Inc. announced that the Chinese National Medical Products Administration has approved CAN108 to be marketed for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
CANbridge Pharmaceuticals, Inc. announced that the Chinese National Medical Products Administration has approved CAN108 to be marketed for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.